

PANCREATIC

Treatment Breakthrough

IMPROVE SURVIVAL OUTCOMES

Fuel your treatment plans




NEW
Perthera Report® Pancreatic

Boost the accuracy of your frontline pancreatic chemotherapy selection

Introducing the Perthera Report® Pancreatic – which includes the world's first and only clinically proven, AI-powered tool that predicts frontline chemotherapy response for newly diagnosed metastatic pancreatic cancer patients.

With this revolutionary advancement you can eliminate treatment uncertainty, replacing trial-and-error approaches with data-driven precision, transforming the standard of care for one of oncology's most challenging diseases.



The chemo predictor score applies to newly diagnosed, Pancreatic Ductal Adenocarcinoma patients.

"Empowering oncologists with data-driven predictions to choose amongst standard of care therapy options can significantly improve outcomes for patients with pancreatic cancer."

Anna Berkenblit, MD, MMSc, Chief Scientific and Medical Officer at PanCAN



The Perthera Report Pancreatic creates ranked, patient specific, treatment options including:



Standard of care therapies

Clinical trials

Expanded access

Patients who receive matched therapies following molecular profiling live longer

Median Overall Survival

1.32 Years Patients without actionable alterations

1.51 Years Patients with actionable alterations / Not on matched therapies

2.32 Years Patients with actionable alterations / On matched therapies

Source: Pishvaian et al; Lancet Oncology; 2020

We built our Chemo Predictor over a decade and on a rigorously tested, scientific foundation

1. We developed the AI predictor utilizing our extensive dataset, the largest real-world pancreatic cancer dataset globally
2. We confirmed our findings through studies published in the *Journal of Clinical Oncology* and showcased at ASCO 2023 and ASCO GI 2025

World's First AI Chemo Predictor

Eliminates a trial-and-error approach with **FOLFIRINOX** and **Gem/nab-P** treatment for newly diagnosed PDAC patients

"In pancreatic cancer, selecting the right treatment first is not just a preference—it's a necessity. The Perthera Report Pancreatic makes this possible for the first time in medical history."

Emanuel Petricoin PhD, Chief Science Officer and Co-Founder of Perthera

Perthera is a leader in AI-driven, precision oncology solutions

Perthera, *The Therapeutic Intelligence Company*, has patented technology utilized at over 600 cancer treatment centers across the United States, supporting more than 1,500 oncologists.

Leading biopharma companies and institutions such as the DOD Cancer Moonshot Program, have leveraged the Perthera Precision Oncology Platform.

Give your pancreatic cancer patient every advantage

Order a Perthera Report Pancreatic today.

- Submit an online request at: www.perthera.com/order
- Email us at: contactus@perthera.com
- Call us at: **703-286-0780**

